Skip NavigationSkip to Content
Return Return to Search Results

CpG Oligonucleotides as Vaccine Adjuvants

  1. Author:
    Kayraklioglu, Neslihan
    Horuluoglu, Begum
    Klinman,Dennis

  2. Author Address

    National Cancer Institute, NIH, Frederick, MD, USA., National Cancer Institute, NIH, Frederick, MD, USA. klinmand@gmail.com., Leitman Klinman Consulting, Potomac, MD, USA. klinmand@gmail.com.,
    1. Year: 2021
  2. Journal: DNA VACCINES
    1. 2197
    2. Pages: 51-85
  4. Type of Article: Book Chapter
  5. ISSN: 978-1-0716-0871-5
  1. Abstract:

    CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid dendritic cells and B cells and triggers an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. This chapter reviews recent progress in understanding the mechanism of action of CpG ODN and provides an overview of human clinical trial results using CpG ODN to improve vaccines for the prevention/treatment of cancer, allergy, and infectious disease.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/978-1-0716-0872-2_4
  3. PMID: 32827132
  4. View record in Web of Science®
  5. WOS: 000687311400005

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel